## Clinical Presentation & Key Findings **Key Point:** Painless jaundice with a palpable gallbladder (Courvoisier sign) and imaging evidence of CBD obstruction at the pancreatic head is pathognomonic for pancreatic head malignancy until proven otherwise. ## Imaging Interpretation The ultrasound findings are classic: - Dilated CBD (>10 mm is abnormal; >12 mm is significant) - **Abrupt transition point** at the pancreatic head — this is the critical clue - Distended but stone-free gallbladder (Courvoisier gallbladder) - No intrahepatic bile duct stones or stricture pattern ## Differential Diagnosis Logic | Feature | Pancreatic CA | Choledocholithiasis | PBC | Stricture | |---------|---------------|-------------------|-----|----------| | Courvoisier sign | **Yes** | Rare | No | No | | Abrupt CBD transition | **Yes** | Gradual/irregular | Progressive | Focal narrowing | | Stone visibility | No | **Yes, visible** | No | No | | Painless onset | **Yes, typical** | Usually painful | Insidious | Variable | | Gallbladder distension | **Yes** | Often contracted | No | No | **High-Yield:** The **Courvoisier sign** (palpable gallbladder + jaundice) occurs in pancreatic cancer because the duct obstruction is distal, allowing proximal dilation and gallbladder filling. In choledocholithiasis, the gallbladder is usually contracted from prior inflammation. ## Why This Is Pancreatic Cancer 1. **Painless jaundice** — classic presentation; stones typically cause pain 2. **Abrupt CBD transition** — suggests a mass at the head, not a stone or stricture 3. **Courvoisier sign** — highly specific for distal bile duct obstruction from malignancy 4. **No visible stone** — rules out lithiasis **Clinical Pearl:** Pancreatic head cancer accounts for ~70% of pancreatic malignancies and typically presents late (stage III–IV) because the retroperitoneal location delays symptoms until biliary obstruction occurs. ## Next Steps Confirm with **CT with contrast** (pancreatic protocol) to assess: - Tumor size and local invasion - Vascular involvement (superior mesenteric vessels, portal vein) - Metastatic disease - Resectability Then **MRCP or ERCP** for tissue diagnosis and therapeutic stent placement if unresectable. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.